Full text data of MIA
MIA
[Confidence: low (only semi-automatic identification from reviews)]
Melanoma-derived growth regulatory protein (Melanoma inhibitory activity protein; Flags: Precursor)
Note: presumably soluble (membrane word is not in UniProt keywords or features)
Melanoma-derived growth regulatory protein (Melanoma inhibitory activity protein; Flags: Precursor)
Note: presumably soluble (membrane word is not in UniProt keywords or features)
UniProt
Q16674
ID MIA_HUMAN Reviewed; 131 AA.
AC Q16674; Q6FHV3;
DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
read moreDT 01-NOV-1997, sequence version 1.
DT 22-JAN-2014, entry version 123.
DE RecName: Full=Melanoma-derived growth regulatory protein;
DE AltName: Full=Melanoma inhibitory activity protein;
DE Flags: Precursor;
GN Name=MIA;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RX PubMed=7923218;
RA Blesch A., Bosserhoff A.-K., Apfel R., Behl C., Hessdoerfer B.,
RA Schmitt A., Jachimczak P., Lottspeich F., Buettner R., Bogdahn U.;
RT "Cloning of a novel malignant melanoma-derived growth-regulatory
RT protein, MIA.";
RL Cancer Res. 54:5695-5701(1994).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC TISSUE=Placenta;
RX PubMed=8550608; DOI=10.1074/jbc.271.1.490;
RA Bosserhoff A.-K., Hein R., Bogdahn U., Buettner R.;
RT "Structure and promoter analysis of the gene encoding the human
RT melanoma-inhibiting protein MIA.";
RL J. Biol. Chem. 271:490-495(1996).
RN [3]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), AND
RP ALTERNATIVE SPLICING.
RX PubMed=12230496; DOI=10.1046/j.1523-1747.2002.00501.x;
RA Hau P., Wise P., Bosserhoff A.K., Blesch A., Jachimczak P.,
RA Tschertner I., Bogdahn U., Apfel R.;
RT "Cloning and characterization of the expression pattern of a novel
RT splice product MIA (splice) of malignant melanoma-derived growth-
RT inhibiting activity (MIA/CD-RAP).";
RL J. Invest. Dermatol. 119:562-569(2002).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA Phelan M., Farmer A.;
RT "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT vector.";
RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT "Cloning of human full open reading frames in Gateway(TM) system entry
RT vector (pDONR201).";
RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA Venter J.C.;
RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN [7]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC TISSUE=Skin;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA
RT project: the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [8]
RP PROTEIN SEQUENCE OF 25-39.
RX PubMed=15340161; DOI=10.1110/ps.04682504;
RA Zhang Z., Henzel W.J.;
RT "Signal peptide prediction based on analysis of experimentally
RT verified cleavage sites.";
RL Protein Sci. 13:2819-2824(2004).
RN [9]
RP INTERACTION WITH FASLG.
RX PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA Voss M., Lettau M., Janssen O.;
RT "Identification of SH3 domain interaction partners of human FasL
RT (CD178) by phage display screening.";
RL BMC Immunol. 10:53-53(2009).
RN [10]
RP INTERACTION WITH TMIGD2.
RX PubMed=22419821; DOI=10.1091/mbc.E11-11-0934;
RA Rahimi N., Rezazadeh K., Mahoney J.E., Hartsough E., Meyer R.D.;
RT "Identification of IGPR-1 as a novel adhesion molecule involved in
RT angiogenesis.";
RL Mol. Biol. Cell 23:1646-1656(2012).
RN [11]
RP X-RAY CRYSTALLOGRAPHY (1.39 ANGSTROMS) OF 25-131.
RX PubMed=11331761; DOI=10.1073/pnas.091601698;
RA Lougheed J.C., Holton J.M., Alber T., Bazan J.F., Handel T.M.;
RT "Structure of melanoma inhibitory activity protein, a member of a
RT recently identified family of secreted proteins.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:5515-5520(2001).
CC -!- FUNCTION: Elicits growth inhibition on melanoma cells in vitro as
CC well as some other neuroectodermal tumors, including gliomas.
CC -!- SUBUNIT: Interacts with FASLG. Interacts with TMIGD2.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=Q16674-1; Sequence=Displayed;
CC Name=2; Synonyms=MIA-splice;
CC IsoId=Q16674-2; Sequence=VSP_044450;
CC -!- TISSUE SPECIFICITY: All malignant melanoma cell lines tested and
CC infrequently in glioma cell lines.
CC -!- PTM: May possess two intramolecular disulfide bonds.
CC -!- SIMILARITY: Belongs to the MIA/OTOR family.
CC -!- SIMILARITY: Contains 1 SH3 domain.
CC -----------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----------------------------------------------------------------------
DR EMBL; X75450; CAA53203.1; -; mRNA.
DR EMBL; X84707; CAA59195.1; -; Genomic_DNA.
DR EMBL; BT007044; AAP35693.1; -; mRNA.
DR EMBL; CR541648; CAG46449.1; -; mRNA.
DR EMBL; CH471126; EAW56997.1; -; Genomic_DNA.
DR EMBL; BC005910; AAH05910.1; -; mRNA.
DR PIR; I38019; I38019.
DR RefSeq; NP_001189482.1; NM_001202553.1.
DR RefSeq; NP_006524.1; NM_006533.3.
DR UniGene; Hs.646364; -.
DR PDB; 1HJD; NMR; -; A=31-131.
DR PDB; 1I1J; X-ray; 1.39 A; A/B=25-131.
DR PDB; 1K0X; NMR; -; A=25-131.
DR PDBsum; 1HJD; -.
DR PDBsum; 1I1J; -.
DR PDBsum; 1K0X; -.
DR ProteinModelPortal; Q16674; -.
DR SMR; Q16674; 25-131.
DR IntAct; Q16674; 1.
DR STRING; 9606.ENSP00000263369; -.
DR PhosphoSite; Q16674; -.
DR DMDM; 2498559; -.
DR PaxDb; Q16674; -.
DR PRIDE; Q16674; -.
DR DNASU; 8190; -.
DR Ensembl; ENST00000263369; ENSP00000263369; ENSG00000261857.
DR Ensembl; ENST00000594436; ENSP00000470129; ENSG00000261857.
DR Ensembl; ENST00000597784; ENSP00000469499; ENSG00000261857.
DR GeneID; 8190; -.
DR KEGG; hsa:8190; -.
DR UCSC; uc002opb.4; human.
DR CTD; 8190; -.
DR GeneCards; GC19P041283; -.
DR HGNC; HGNC:7076; MIA.
DR HPA; HPA042369; -.
DR MIM; 601340; gene.
DR neXtProt; NX_Q16674; -.
DR PharmGKB; PA30800; -.
DR eggNOG; NOG43576; -.
DR HOGENOM; HOG000063668; -.
DR HOVERGEN; HBG000503; -.
DR InParanoid; Q16674; -.
DR KO; K16655; -.
DR OMA; DCRFIPI; -.
DR PhylomeDB; Q16674; -.
DR EvolutionaryTrace; Q16674; -.
DR GeneWiki; Melanoma_inhibitory_activity; -.
DR GenomeRNAi; 8190; -.
DR NextBio; 30882; -.
DR PRO; PR:Q16674; -.
DR ArrayExpress; Q16674; -.
DR Bgee; Q16674; -.
DR CleanEx; HS_MIA; -.
DR Genevestigator; Q16674; -.
DR GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR InterPro; IPR011511; SH3_2.
DR InterPro; IPR001452; SH3_domain.
DR Pfam; PF07653; SH3_2; 1.
DR SMART; SM00326; SH3; 1.
DR SUPFAM; SSF50044; SSF50044; 1.
DR PROSITE; PS50002; SH3; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Alternative splicing; Complete proteome;
KW Direct protein sequencing; Disulfide bond; Growth factor;
KW Reference proteome; Secreted; SH3 domain; Signal.
FT SIGNAL 1 24
FT CHAIN 25 131 Melanoma-derived growth regulatory
FT protein.
FT /FTId=PRO_0000019028.
FT DOMAIN 43 113 SH3.
FT DISULFID 36 41
FT DISULFID 59 130
FT VAR_SEQ 43 131 HPISMAVALQDYMAPDCRFLTIHRGQVVYVFSKLKGRGRLF
FT WGGSVQGDYYGDLAARLGYFPSSIVREDQTLKPGKVDVKTD
FT KWDFYCQ -> RSGRLLWRSGCSPGLFPQ (in isoform
FT 2).
FT /FTId=VSP_044450.
FT STRAND 32 38
FT STRAND 45 52
FT STRAND 57 61
FT STRAND 69 76
FT HELIX 78 80
FT STRAND 83 89
FT STRAND 101 104
FT HELIX 105 107
FT STRAND 108 113
FT STRAND 119 122
SQ SEQUENCE 131 AA; 14509 MW; 4D3BB30BD6008BDC CRC64;
MARSLVCLGV IILLSAFSGP GVRGGPMPKL ADRKLCADQE CSHPISMAVA LQDYMAPDCR
FLTIHRGQVV YVFSKLKGRG RLFWGGSVQG DYYGDLAARL GYFPSSIVRE DQTLKPGKVD
VKTDKWDFYC Q
//
ID MIA_HUMAN Reviewed; 131 AA.
AC Q16674; Q6FHV3;
DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
read moreDT 01-NOV-1997, sequence version 1.
DT 22-JAN-2014, entry version 123.
DE RecName: Full=Melanoma-derived growth regulatory protein;
DE AltName: Full=Melanoma inhibitory activity protein;
DE Flags: Precursor;
GN Name=MIA;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RX PubMed=7923218;
RA Blesch A., Bosserhoff A.-K., Apfel R., Behl C., Hessdoerfer B.,
RA Schmitt A., Jachimczak P., Lottspeich F., Buettner R., Bogdahn U.;
RT "Cloning of a novel malignant melanoma-derived growth-regulatory
RT protein, MIA.";
RL Cancer Res. 54:5695-5701(1994).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC TISSUE=Placenta;
RX PubMed=8550608; DOI=10.1074/jbc.271.1.490;
RA Bosserhoff A.-K., Hein R., Bogdahn U., Buettner R.;
RT "Structure and promoter analysis of the gene encoding the human
RT melanoma-inhibiting protein MIA.";
RL J. Biol. Chem. 271:490-495(1996).
RN [3]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), AND
RP ALTERNATIVE SPLICING.
RX PubMed=12230496; DOI=10.1046/j.1523-1747.2002.00501.x;
RA Hau P., Wise P., Bosserhoff A.K., Blesch A., Jachimczak P.,
RA Tschertner I., Bogdahn U., Apfel R.;
RT "Cloning and characterization of the expression pattern of a novel
RT splice product MIA (splice) of malignant melanoma-derived growth-
RT inhibiting activity (MIA/CD-RAP).";
RL J. Invest. Dermatol. 119:562-569(2002).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA Phelan M., Farmer A.;
RT "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT vector.";
RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT "Cloning of human full open reading frames in Gateway(TM) system entry
RT vector (pDONR201).";
RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA Venter J.C.;
RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN [7]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC TISSUE=Skin;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA
RT project: the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [8]
RP PROTEIN SEQUENCE OF 25-39.
RX PubMed=15340161; DOI=10.1110/ps.04682504;
RA Zhang Z., Henzel W.J.;
RT "Signal peptide prediction based on analysis of experimentally
RT verified cleavage sites.";
RL Protein Sci. 13:2819-2824(2004).
RN [9]
RP INTERACTION WITH FASLG.
RX PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA Voss M., Lettau M., Janssen O.;
RT "Identification of SH3 domain interaction partners of human FasL
RT (CD178) by phage display screening.";
RL BMC Immunol. 10:53-53(2009).
RN [10]
RP INTERACTION WITH TMIGD2.
RX PubMed=22419821; DOI=10.1091/mbc.E11-11-0934;
RA Rahimi N., Rezazadeh K., Mahoney J.E., Hartsough E., Meyer R.D.;
RT "Identification of IGPR-1 as a novel adhesion molecule involved in
RT angiogenesis.";
RL Mol. Biol. Cell 23:1646-1656(2012).
RN [11]
RP X-RAY CRYSTALLOGRAPHY (1.39 ANGSTROMS) OF 25-131.
RX PubMed=11331761; DOI=10.1073/pnas.091601698;
RA Lougheed J.C., Holton J.M., Alber T., Bazan J.F., Handel T.M.;
RT "Structure of melanoma inhibitory activity protein, a member of a
RT recently identified family of secreted proteins.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:5515-5520(2001).
CC -!- FUNCTION: Elicits growth inhibition on melanoma cells in vitro as
CC well as some other neuroectodermal tumors, including gliomas.
CC -!- SUBUNIT: Interacts with FASLG. Interacts with TMIGD2.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=Q16674-1; Sequence=Displayed;
CC Name=2; Synonyms=MIA-splice;
CC IsoId=Q16674-2; Sequence=VSP_044450;
CC -!- TISSUE SPECIFICITY: All malignant melanoma cell lines tested and
CC infrequently in glioma cell lines.
CC -!- PTM: May possess two intramolecular disulfide bonds.
CC -!- SIMILARITY: Belongs to the MIA/OTOR family.
CC -!- SIMILARITY: Contains 1 SH3 domain.
CC -----------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----------------------------------------------------------------------
DR EMBL; X75450; CAA53203.1; -; mRNA.
DR EMBL; X84707; CAA59195.1; -; Genomic_DNA.
DR EMBL; BT007044; AAP35693.1; -; mRNA.
DR EMBL; CR541648; CAG46449.1; -; mRNA.
DR EMBL; CH471126; EAW56997.1; -; Genomic_DNA.
DR EMBL; BC005910; AAH05910.1; -; mRNA.
DR PIR; I38019; I38019.
DR RefSeq; NP_001189482.1; NM_001202553.1.
DR RefSeq; NP_006524.1; NM_006533.3.
DR UniGene; Hs.646364; -.
DR PDB; 1HJD; NMR; -; A=31-131.
DR PDB; 1I1J; X-ray; 1.39 A; A/B=25-131.
DR PDB; 1K0X; NMR; -; A=25-131.
DR PDBsum; 1HJD; -.
DR PDBsum; 1I1J; -.
DR PDBsum; 1K0X; -.
DR ProteinModelPortal; Q16674; -.
DR SMR; Q16674; 25-131.
DR IntAct; Q16674; 1.
DR STRING; 9606.ENSP00000263369; -.
DR PhosphoSite; Q16674; -.
DR DMDM; 2498559; -.
DR PaxDb; Q16674; -.
DR PRIDE; Q16674; -.
DR DNASU; 8190; -.
DR Ensembl; ENST00000263369; ENSP00000263369; ENSG00000261857.
DR Ensembl; ENST00000594436; ENSP00000470129; ENSG00000261857.
DR Ensembl; ENST00000597784; ENSP00000469499; ENSG00000261857.
DR GeneID; 8190; -.
DR KEGG; hsa:8190; -.
DR UCSC; uc002opb.4; human.
DR CTD; 8190; -.
DR GeneCards; GC19P041283; -.
DR HGNC; HGNC:7076; MIA.
DR HPA; HPA042369; -.
DR MIM; 601340; gene.
DR neXtProt; NX_Q16674; -.
DR PharmGKB; PA30800; -.
DR eggNOG; NOG43576; -.
DR HOGENOM; HOG000063668; -.
DR HOVERGEN; HBG000503; -.
DR InParanoid; Q16674; -.
DR KO; K16655; -.
DR OMA; DCRFIPI; -.
DR PhylomeDB; Q16674; -.
DR EvolutionaryTrace; Q16674; -.
DR GeneWiki; Melanoma_inhibitory_activity; -.
DR GenomeRNAi; 8190; -.
DR NextBio; 30882; -.
DR PRO; PR:Q16674; -.
DR ArrayExpress; Q16674; -.
DR Bgee; Q16674; -.
DR CleanEx; HS_MIA; -.
DR Genevestigator; Q16674; -.
DR GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR InterPro; IPR011511; SH3_2.
DR InterPro; IPR001452; SH3_domain.
DR Pfam; PF07653; SH3_2; 1.
DR SMART; SM00326; SH3; 1.
DR SUPFAM; SSF50044; SSF50044; 1.
DR PROSITE; PS50002; SH3; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Alternative splicing; Complete proteome;
KW Direct protein sequencing; Disulfide bond; Growth factor;
KW Reference proteome; Secreted; SH3 domain; Signal.
FT SIGNAL 1 24
FT CHAIN 25 131 Melanoma-derived growth regulatory
FT protein.
FT /FTId=PRO_0000019028.
FT DOMAIN 43 113 SH3.
FT DISULFID 36 41
FT DISULFID 59 130
FT VAR_SEQ 43 131 HPISMAVALQDYMAPDCRFLTIHRGQVVYVFSKLKGRGRLF
FT WGGSVQGDYYGDLAARLGYFPSSIVREDQTLKPGKVDVKTD
FT KWDFYCQ -> RSGRLLWRSGCSPGLFPQ (in isoform
FT 2).
FT /FTId=VSP_044450.
FT STRAND 32 38
FT STRAND 45 52
FT STRAND 57 61
FT STRAND 69 76
FT HELIX 78 80
FT STRAND 83 89
FT STRAND 101 104
FT HELIX 105 107
FT STRAND 108 113
FT STRAND 119 122
SQ SEQUENCE 131 AA; 14509 MW; 4D3BB30BD6008BDC CRC64;
MARSLVCLGV IILLSAFSGP GVRGGPMPKL ADRKLCADQE CSHPISMAVA LQDYMAPDCR
FLTIHRGQVV YVFSKLKGRG RLFWGGSVQG DYYGDLAARL GYFPSSIVRE DQTLKPGKVD
VKTDKWDFYC Q
//
MIM
601340
*RECORD*
*FIELD* NO
601340
*FIELD* TI
*601340 MELANOMA INHIBITORY ACTIVITY PROTEIN; MIA
;;CARTILAGE-DERIVED RETINOIC ACID-SENSITIVE PROTEIN; CDRAP
read more*FIELD* TX
CLONING
Growth and expansion of tumor cells including malignant melanomas are
modulated by a complex network of growth factors, which regulate
proliferation and cell-matrix interaction through a variety of different
signal transduction pathways. Blesch et al. (1994) purified a protein
they called melanoma inhibitory activity (MIA) which is secreted by
malignant melanoma cells and elicits growth inhibition of melanoma cells
in vitro. Bosserhoff et al. (1996) cloned the gene encoding MIA and
described its genomic organization. The gene encodes a 131-amino acid
prepropolypeptide with a 24-residue secretion signal peptide sequence.
The authors identified the transcription start site of the gene and
studied the expression characteristics of the gene promoter in human
melanoma, epithelial, and undifferentiated cells. Bosserhoff et al.
(1996) found by Northern blot analysis that the MIA gene was expressed
in all melanoma cell lines tested but was not expressed in fibroblast or
epithelial cell lines.
GENE STRUCTURE
Bosserhoff et al. (1996) determined that the MIA gene comprises 4 exons.
BIOCHEMICAL FEATURES
Bosserhoff et al. (1997) determined that MIA levels in patients with
metastatic malignant melanoma were significantly above the 97th
percentile level (6.5 ng/ml) determined for 72 normal controls. In a
blinded, multicenter trial, Bosserhoff et al. (2000) analyzed serum MIA
levels by ELISA in 259 patients with stage III and stage IV metastatic
malignant melanoma. MIA levels were elevated in both groups and
decreased significantly after surgery. MIA levels subsequently increased
in 29 of 34 patients with rapid disease progression and decreased in 5
patients who responded to immunochemotherapy. Bosserhoff et al. (2000)
suggested that MIA levels have prognostic value in staging and
monitoring tumor load in malignant melanoma.
- Crystal Structure
Lougheed et al. (2001) reported the crystal structure of human MIA. They
stated that this was the first structural characterization of a secreted
protein with an SH3 subdomain.
MAPPING
Koehler et al. (1996) mapped the MIA gene to 19q13.32-q13.33 by
fluorescence in situ hybridization.
*FIELD* RF
1. Blesch, A.; Bosserhoff, A.; Apfel, R.; Behl, C.; Hessdoerfer, B;
Schmitt, A.; Jachimczak, P.; Lottspeich, F.; Buettner, R.; Bogdahn,
U.: Cloning of a novel malignant melanoma-derived growth-regulatory
protein, MIA. Cancer Res. 54: 5695-5701, 1994.
2. Bosserhoff, A. K.; Hauschild, A.; Hein, R.; Schadendorf, D.; Stockfleth,
E.; Bogenrieder, T.; Landthaler, M.; Buettner, R.; Stolz, W.: Elevated
MIA serum levels are of relevance for management of metastasized malignant
melanomas: results of a German multicenter study. J. Invest. Derm. 114:
395-396, 2000.
3. Bosserhoff, A. K.; Hein, R.; Bogdahn, U.; Buettner, R.: Structure
and promoter analysis of the gene encoding the human melanoma-inhibiting
protein MIA. J. Biol. Chem. 271: 490-495, 1996.
4. Bosserhoff, A. K.; Kaufmann, M.; Kaluza, B.; Bartke, I.; Zirngibl,
H.; Hein, R.; Stolz, W.; Buettner, R.: Melanoma-inhibiting activity,
a novel serum marker for progression of malignant melanoma. Cancer
Res. 57: 3149-3153, 1997.
5. Koehler, M. R.; Bosserhoff, A.-K.; von Beust, G.; Bauer, A.; Blesch,
A.; Buettner, R.; Schlegel, J.; Bogdahn, U.; Schmid, M.: Assignment
of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33
by fluorescence in situ hybridization (FISH). Genomics 35: 265-267,
1996.
6. Lougheed, J. C.; Holton, J. M.; Alber, T.; Bazan, J. F.; Handel,
T. M.: Structure of melanoma inhibitory activity protein, a member
of a recently identified family of secreted proteins. Proc. Nat.
Acad. Sci. 98: 5515-5520, 2001.
*FIELD* CN
Victor A. McKusick - updated: 6/1/2001
Gary A. Bellus - updated: 6/13/2000
*FIELD* CD
Mark H. Paalman: 7/9/1996
*FIELD* ED
alopez: 03/22/2005
mgross: 7/30/2003
mcapotos: 6/7/2001
terry: 6/1/2001
alopez: 6/13/2000
mcapotos: 12/8/1999
terry: 7/9/1997
terry: 12/11/1996
terry: 7/24/1996
terry: 7/15/1996
mark: 7/9/1996
*RECORD*
*FIELD* NO
601340
*FIELD* TI
*601340 MELANOMA INHIBITORY ACTIVITY PROTEIN; MIA
;;CARTILAGE-DERIVED RETINOIC ACID-SENSITIVE PROTEIN; CDRAP
read more*FIELD* TX
CLONING
Growth and expansion of tumor cells including malignant melanomas are
modulated by a complex network of growth factors, which regulate
proliferation and cell-matrix interaction through a variety of different
signal transduction pathways. Blesch et al. (1994) purified a protein
they called melanoma inhibitory activity (MIA) which is secreted by
malignant melanoma cells and elicits growth inhibition of melanoma cells
in vitro. Bosserhoff et al. (1996) cloned the gene encoding MIA and
described its genomic organization. The gene encodes a 131-amino acid
prepropolypeptide with a 24-residue secretion signal peptide sequence.
The authors identified the transcription start site of the gene and
studied the expression characteristics of the gene promoter in human
melanoma, epithelial, and undifferentiated cells. Bosserhoff et al.
(1996) found by Northern blot analysis that the MIA gene was expressed
in all melanoma cell lines tested but was not expressed in fibroblast or
epithelial cell lines.
GENE STRUCTURE
Bosserhoff et al. (1996) determined that the MIA gene comprises 4 exons.
BIOCHEMICAL FEATURES
Bosserhoff et al. (1997) determined that MIA levels in patients with
metastatic malignant melanoma were significantly above the 97th
percentile level (6.5 ng/ml) determined for 72 normal controls. In a
blinded, multicenter trial, Bosserhoff et al. (2000) analyzed serum MIA
levels by ELISA in 259 patients with stage III and stage IV metastatic
malignant melanoma. MIA levels were elevated in both groups and
decreased significantly after surgery. MIA levels subsequently increased
in 29 of 34 patients with rapid disease progression and decreased in 5
patients who responded to immunochemotherapy. Bosserhoff et al. (2000)
suggested that MIA levels have prognostic value in staging and
monitoring tumor load in malignant melanoma.
- Crystal Structure
Lougheed et al. (2001) reported the crystal structure of human MIA. They
stated that this was the first structural characterization of a secreted
protein with an SH3 subdomain.
MAPPING
Koehler et al. (1996) mapped the MIA gene to 19q13.32-q13.33 by
fluorescence in situ hybridization.
*FIELD* RF
1. Blesch, A.; Bosserhoff, A.; Apfel, R.; Behl, C.; Hessdoerfer, B;
Schmitt, A.; Jachimczak, P.; Lottspeich, F.; Buettner, R.; Bogdahn,
U.: Cloning of a novel malignant melanoma-derived growth-regulatory
protein, MIA. Cancer Res. 54: 5695-5701, 1994.
2. Bosserhoff, A. K.; Hauschild, A.; Hein, R.; Schadendorf, D.; Stockfleth,
E.; Bogenrieder, T.; Landthaler, M.; Buettner, R.; Stolz, W.: Elevated
MIA serum levels are of relevance for management of metastasized malignant
melanomas: results of a German multicenter study. J. Invest. Derm. 114:
395-396, 2000.
3. Bosserhoff, A. K.; Hein, R.; Bogdahn, U.; Buettner, R.: Structure
and promoter analysis of the gene encoding the human melanoma-inhibiting
protein MIA. J. Biol. Chem. 271: 490-495, 1996.
4. Bosserhoff, A. K.; Kaufmann, M.; Kaluza, B.; Bartke, I.; Zirngibl,
H.; Hein, R.; Stolz, W.; Buettner, R.: Melanoma-inhibiting activity,
a novel serum marker for progression of malignant melanoma. Cancer
Res. 57: 3149-3153, 1997.
5. Koehler, M. R.; Bosserhoff, A.-K.; von Beust, G.; Bauer, A.; Blesch,
A.; Buettner, R.; Schlegel, J.; Bogdahn, U.; Schmid, M.: Assignment
of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33
by fluorescence in situ hybridization (FISH). Genomics 35: 265-267,
1996.
6. Lougheed, J. C.; Holton, J. M.; Alber, T.; Bazan, J. F.; Handel,
T. M.: Structure of melanoma inhibitory activity protein, a member
of a recently identified family of secreted proteins. Proc. Nat.
Acad. Sci. 98: 5515-5520, 2001.
*FIELD* CN
Victor A. McKusick - updated: 6/1/2001
Gary A. Bellus - updated: 6/13/2000
*FIELD* CD
Mark H. Paalman: 7/9/1996
*FIELD* ED
alopez: 03/22/2005
mgross: 7/30/2003
mcapotos: 6/7/2001
terry: 6/1/2001
alopez: 6/13/2000
mcapotos: 12/8/1999
terry: 7/9/1997
terry: 12/11/1996
terry: 7/24/1996
terry: 7/15/1996
mark: 7/9/1996